Q-linea AB (publ) announces today that it has signed a contract with a major U.S. health system in the mid-Atlantic region for deployment of its ASTar® rapid antimicrobial susceptibility testing (AST) system.
This installation will serve an integrated network with more than 1,500 hospital beds with a strong reputation for clinical excellence and innovation. The installation represents an important milestone for Q-linea's U.S. business as it is the first new deployment following FDA clearance of the expanded panel.
"This contract represents a major step forward for Q-linea in the United States," said Stuart Gander, President and CEO of Q-linea. "We are pleased to see that the leading healthcare systems are looking to ASTar to serve high-volume laboratories efficiently while delivering improved patient testing for their clinical teams."
For more information, please contact:
Stuart Gander, President & CEO, Q-linea
Stuart.Gander@qlinea.com
Annika Blondeau Henriksson, Interim CFO & IR, Q-linea AB
IR@linea.com
+46 (0) 70-600 15 20
About Q-linea
Q-linea AB (publ) is an innovative infection diagnostics company dedicated to saving lives and reducing healthcare costs by developing and delivering solutions for the rapid diagnosis and treatment of infectious diseases. The company's core focus is on rapid Antibiotic Susceptibility Testing (rAST), a critical step in the treatment of sepsis and other severe infections.
Q-linea's flagship technology, ASTar®, is a fully automated instrument designed to deliver rapid phenotypic AST results directly from positive blood cultures in approximately six hours. By significantly reducing the time to answer compared to traditional methods, Q-linea enables physicians to prescribe the optimal antibiotic treatment sooner, improving patient outcomes and actively combating the global threat of antimicrobial resistance (AMR). Founded in 2008 and headquartered in Uppsala, Sweden, Q-linea AB is listed on Nasdaq Stockholm (STO:QLINEA).
